570 related articles for article (PubMed ID: 25186970)
1. Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience.
Sciarra A; Gentile V; Cattarino S; Gentilucci A; Alfarone A; D'Eramo G; Salciccia S
Int J Urol; 2015 Jan; 22(1):98-103. PubMed ID: 25186970
[TBL] [Abstract][Full Text] [Related]
2. Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
Hakariya T; Shida Y; Tsurusaki T; Watanabe J; Furukawa M; Matsuya F; Miyata Y; Sakai H
Int J Urol; 2018 May; 25(5):464-470. PubMed ID: 29521011
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy of ethinylestradiol for castration-resistant prostate cancer].
Hayashi T; Sekii Y; Katayama K; Kamoto A; Kakuta Y; Mori N; Itatani H; Yoshioka T
Nihon Hinyokika Gakkai Zasshi; 2014 Apr; 105(2):37-42. PubMed ID: 24908814
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer.
Roviello G; Zanotti L; Gobbi A; Dester M; Generali D; Pacifico C; Cappelletti MR; Bonetta A
Clin Genitourin Cancer; 2017 Jun; 15(3):371-375. PubMed ID: 27692697
[TBL] [Abstract][Full Text] [Related]
7. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
8. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer.
Onishi T; Shibahara T; Masui S; Sugino Y; Higashi S; Sasaki T
Anticancer Res; 2016 Jun; 36(6):2999-3004. PubMed ID: 27272817
[TBL] [Abstract][Full Text] [Related]
11. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer.
Nakano T; Kadono Y; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Mizokami A
Anticancer Res; 2020 Apr; 40(4):2291-2296. PubMed ID: 32234928
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
15. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Bianco V; Ponchietti R; Barbanti G; Francini E
Clin Genitourin Cancer; 2015 Oct; 13(5):441-6. PubMed ID: 25920994
[TBL] [Abstract][Full Text] [Related]
17. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
18. Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.
Izumi K; Kadono Y; Shima T; Konaka H; Mizokami A; Koh E; Namiki M
Anticancer Res; 2010 Dec; 30(12):5201-5. PubMed ID: 21187513
[TBL] [Abstract][Full Text] [Related]
19. Understanding heterogeneity of treatment effect in prostate cancer.
Aly A; Mullins CD; Hussain A
Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
[TBL] [Abstract][Full Text] [Related]
20. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]